Wanted pages
From Glioblastoma Treatments
Jump to navigationJump to search
List of non-existing pages with the most links to them, excluding pages which only have redirects linking to them. For a list of non-existent pages that have redirects linking to them, see the list of broken redirects.
Showing below up to 25 results in range #351 to #375.
- Under investigation; some studies suggest potential for improved outcomes in cancer patients on metformin (1 link)
- Used in various studies for cancer treatment (1 link)
- Valproic acid users: retrospective study shows median survival of 16.9 months, prospective study shows 29.6 months (1 link)
- Variable across studies; for example, a study combining Temodar with Celebrex showed a PFS-6 of 35%, another combining Celebrex with CPT-11 showed PFS-6 of 25% (1 link)
- Varied, with multiple studies evaluating efficacy and optimal scheduling (1 link)
- Varied; includes studies with mixed outcomes (1 link)
- Varied; one study showed median OS of 41.1 months with vaccine and temozolomide, and another indicated 30.3 months with vaccine and basiliximod. (1 link)
- Varies; cannabis is known for minimal side effects such as dry mouth, red eyes, and increased appetite. Sativex may have additional side effects similar to other cannabis products. (1 link)
- Varies; for leukemia treatment includes fluid retention, nausea, muscle cramps, rashes, and fatigue. Brain tumor studies may have different profiles due to combination treatments and patient population. (1 link)
- Varies; one combination showed median survival of 20 months, another study reported median survival up to 29.6 months with high-dose Valproic Acid (1 link)
- Varies based on the combination; potential for increased chemotherapy toxicity (1 link)
- Varies by drug; includes gastrointestinal upset, fatigue, liver enzyme changes, and potential interactions with other treatments (1 link)
- Varies by specific ARB; can include dizziness, hypotension, and renal function alteration (1 link)
- Varies depending on stage and treatment (1 link)
- Varies depending on stage and treatment; typical survival rates for favorable histology are around 90% for localized disease (1 link)
- Various, given its long history of use (1 link)
- Various, including Phase II (1 link)
- Various, mainly in Japan for cancers like stomach, colon, and non-small cell lung cancer (1 link)
- Various studies, including recent meta-analyses and reviews (1 link)
- Well-tolerated; potential side effects include fishy aftertaste, gastrointestinal discomfort (1 link)
- While initial phase III trial results in newly diagnosed GBM were disappointing, the ReACT trial for recurrent GBM suggests potential benefits, particularly when combined with bevacizumab (1 link)
- Template:Sounds (1 link)
- Template:Всему (1 link)
- Property:Has Common side effects (1 link)
- Property:Has common side effects (1 link)
